


Pertuzumab Blood and lymphatic system disorders Cardiac disorders Ear and Jabrish Helisorders Gastrointestinal disorders HO General disorders and administration site conditions Hiepatobiliary disorders Immune system disorders LT Infections and infestations Injury, poisoning and procedural complications Investigations Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nervous system disorders OT Pregnancy, progressian and portions Reproductive 395ternary Urcase disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Surgitation Surgit Vascular disorders OUTC_COD

soc_name

TDM-1








OUTC_COD

soc_name



OUTC_COD

soc_name

Comparing The Difference of Adverse Events with HER2 Inhibitors: A Study of The FDA Adverse Event Reporting System (FAERS)

Figure Legend

Supplementary Figure 1. Mulberry diagram visualizing the correspondence of adverse events (soc_name) and outcomes (OUTC_COD) reported in cases treated with pertuzumab, TDM-1, lapatinib, neratinib, or tucatinib.